Paeoniflorin inhibits proliferation of endometrial cancer cells via activating MAPK and NF‑κB signaling pathways

Zhang,Jianxin; Wang,Fengchun; Wang,Huali; Wang,Yanna; Wu,Yan; Xu,Hui; Su,Chen

doi:10.3892/etm.2017.5250

Paeoniflorin inhibits proliferation of endometrial cancer cells via activating MAPK and NF‑κB signaling pathways

Authors:
- Jianxin Zhang
- Fengchun Wang
- Huali Wang
- Yanna Wang
- Yan Wu
- Hui Xu
- Chen Su
View Affiliations

Affiliations: Department of Traditional Chinese Medicine, The Second Hospital of Shandong University, Jinan, Shandong 250021, P.R. China, Department of General Surgery, The Second Hospital of Shandong University, Jinan, Shandong 250021, P.R. China, Department of Gynecology, The Second Hospital of Shandong University, Jinan, Shandong 250021, P.R. China
Published online on: October 2, 2017 https://doi.org/10.3892/etm.2017.5250
Pages: 5445-5451
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Paeoniflorin (PAE), a principal bioactive component of Paeonia lactiflora Pall., appears to have antitumor properties. However, the pharmacological activity of PAE in endometrial cancer and the specific mechanisms have remained largely elusive. The present study aimed to determine the antitumor activity of PAE in the human endometrial cancer cell line RL95‑2 and explore the potential mechanisms. Cell proliferation was assessed to evaluate the antitumor effect of PAE towards RL95‑2 cells via a Cell Counting Kit‑8 assay. Protein expression was examined to investigate changes in the signaling pathways of p38 mitogen‑activated protein kinase (MAPK), c‑Jun N‑terminal kinase (JNK), extracellular signal‑regulated kinase (ERK) and nuclear factor (NF)‑κB in RL95‑2 cells during PAE treatment by western blot analysis. The results revealed that PAE significantly and dose‑ and time‑dependently inhibited the proliferation of RL95‑2 cells. In addition, PAE activated MAPK signaling pathways (p38, JNK and ERK) and the NF‑κB signaling pathway. Furthermore, p38 MAPK and NF‑κB inhibitors (SB203580 and MG‑132, respectively) prevented PAE‑induced proliferative inhibition in RL95‑2 cells. However, ERK and JNK inhibitors (PD98059 and BI‑78D3, respectively) did not produce such an inhibition. In conclusion, the present study demonstrated that PAE exerts its anti‑proliferative activity via activating p38 MAPK and NF‑κB signaling pathways in endometrial cancer cells, providing a potential new drug of choice for endometrial cancer therapy.

View Figures

View References

1	Fatima I, Chandra V, Saxena R, Sanghani Y, Hajela K, Negi MP, Sankhwar PL, Jain SK and Dwivedi A: 2,3-diaryl-2H-1-benzopyran derivatives interfere with classical and non-classical estrogen receptor signaling pathways, inhibit akt activation and induce apoptosis in human endometrial cancer cells. Mol Cell Endocrinol. 348:198–210. 2012. View Article : Google Scholar : PubMed/NCBI
2	Alteri R, Bertaut T, Brooks D, et al: Cancer Facts and Figures 2016. Atlanta, GA: American Cancer Society; 2016
3	Horan TC, Zompa MA, Seto CT, Kim KK, Moore RG and Lange TS: Description of the cytotoxic effect of a novel drug abietyl-isothiocyanate on endometrial cancer cell lines. Invest New Drugs. 30:1460–1470. 2012. View Article : Google Scholar : PubMed/NCBI
4	Fleming GF: Systemic chemotherapy for uterine carcinoma: Metastatic and adjuvant. J Clin Oncol. 25:2983–2990. 2007. View Article : Google Scholar : PubMed/NCBI
5	Singapore Cancer Network (SCAN) Gynaecological Cancers Systemic Therapy Workgroup: Singapore cancer network (SCAN) guidelines for the systemic therapy of endometrial (uterine) cancer. Ann Acad Med Singapore. 44:434–439. 2015.PubMed/NCBI
6	Thigpen JT, Brady MF, Homesley HD, Malfetano J, DuBeshter B, Burger RA and Liao S: Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: A gynecologic oncology group study. J Clin Oncol. 22:3902–3908. 2004. View Article : Google Scholar : PubMed/NCBI
7	Li H and Narahara H: 15-Deoxy-Δ(12, 14)-prostaglandin j (2) induces growth inhibition, cell cycle arrest and apoptosis in human endometrial cancer cell lines. Int J Mol Med. 31:778–788. 2013. View Article : Google Scholar : PubMed/NCBI
8	Wu H, Li W, Wang T, Shu Y and Liu P: Paeoniflorin suppress NF-κB activation through modulation of I kappaB alpha and enhances 5-fluorouracil-induced apoptosis in human gastric carcinoma cells. Biomed Pharmacother. 62:659–666. 2008. View Article : Google Scholar : PubMed/NCBI
9	Wang X, Duan X, Yang G, Zhang X, Deng L, Zheng H, Deng C, Wen J, Wang N, Peng C, et al: Honokiol crosses BBB and BCSFB, and inhibits brain tumor growth in rat 9L intracerebral gliosarcoma model and human U251 xenograft glioma model. PLoS One. 6:e184902011. View Article : Google Scholar : PubMed/NCBI
10	Fang S, Zhu W, Zhang Y, Shu Y and Liu P: Paeoniflorin modulates multidrug resistance of a human gastric cancer cell line via the inhibition of NF-κB activation. Mol Med Rep. 5:351–356. 2012.PubMed/NCBI
11	Nie XH, Ou-yang J, Xing Y, Li DY, Dong XY, Liu RE and Xu RX: Paeoniflorin inhibits human glioma cells via STAT3 degradation by the ubiquitin-proteasome pathway. Drug Des Devel Ther. 9:5611–5622. 2015.PubMed/NCBI
12	Zhang J, Dou W, Zhang E, Sun A, Ding L, Wei X, Chou G, Mani S and Wang Z: Paeoniflorin abrogates DSS-induced colitis via a TLR4-dependent pathway. Am J Physiol Gastrointest Liver Physiol. 306:G27–G36. 2014. View Article : Google Scholar : PubMed/NCBI
13	Gan Y, Cui X, Ma T, Liu Y, Li A and Huang M: Paeoniflorin upregulates β-defensin-2 expression in human bronchial epithelial cell through the p38 MAPK, ERK, and NF-κB signaling pathways. Inflammation. 37:1468–1475. 2014. View Article : Google Scholar : PubMed/NCBI
14	Lee B, Shin YW, Bae EA, Han SJ, Kim JS, Kang SS and Kim DH: Antiallergic effect of the root of Paeonia lactiflora and its constituents paeoniflorin and paeonol. Arch Pharm Res. 31:445–450. 2008. View Article : Google Scholar : PubMed/NCBI
15	Chen T, Guo ZP, Wang L, Qin S, Cao N, Li MM, Jia RZ and Wang TT: Paeoniflorin suppresses vascular damage and the expression of E-selectin and ICAM-1 in a mouse model of cutaneous arthus reaction. Exp Dermatol. 22:453–457. 2013. View Article : Google Scholar : PubMed/NCBI
16	Wu H, Wei W, Song L, Zhang L, Chen Y and Hu X: Paeoniflorin induced immune tolerance of mesenteric lymph node lymphocytes via enhancing beta 2-adrenergic receptor desensitization in rats with adjuvant arthritis. Int Immunopharmacol. 7:662–673. 2007. View Article : Google Scholar : PubMed/NCBI
17	He DY and Dai SM: Anti-inflammatory and immunomodulatory effects of Paeonia lactiflora pall., a traditional chinese herbal medicine. Front Pharmacol. 2:102011. View Article : Google Scholar : PubMed/NCBI
18	Dong H, Li R, Yu C, Xu T, Zhang X and Dong M: Paeoniflorin inhibition of 6-hydroxydopamine-induced apoptosis in PC12 cells via suppressing reactive oxygen species-mediated pkcdelta/NF-κB pathway. Neuroscience. 285:70–80. 2015. View Article : Google Scholar : PubMed/NCBI
19	Hung JY, Yang CJ, Tsai YM, Huang HW and Huang MS: Antiproliferative activity of paeoniflorin is through cell cycle arrest and the FAS/FAS ligand-mediated apoptotic pathway in human non-small cell lung cancer A549 cells. Clin Exp Pharmacol Physiol. 35:141–147. 2008. View Article : Google Scholar : PubMed/NCBI
20	Lu JT, He W, Song SS and Wei W: Paeoniflorin inhibited the tumor invasion and metastasis in human hepatocellular carcinoma cells. Bratisl Lek Listy. 115:427–433. 2014.PubMed/NCBI
21	Wang H, Zhou H, Wang CX, Li YS, Xie HY, Luo JD and Zhou Y: Paeoniflorin inhibits growth of human colorectal carcinoma HT 29 cells in vitro and in vivo. Food Chem Toxicol. 50:1560–1567. 2012. View Article : Google Scholar : PubMed/NCBI
22	Li W, Qi Z, Wei Z, Liu S, Wang P, Chen Y and Zhao Y: Paeoniflorin inhibits proliferation and induces apoptosis of human glioma cells via microRNA-16 upregulation and matrix metalloproteinase-9 downregulation. Mol Med Rep. 12:2735–2740. 2015. View Article : Google Scholar : PubMed/NCBI
23	Kim JY, Lee SG, Chung JY, Kim YJ, Park JE, Oh S, Lee SY, Choi HJ, Yoo YH and Kim JM: 7, 12-Dimethylbenzanthracene induces apoptosis in RL95-2 human endometrial cancer cells: Ligand-selective activation of cytochrome P450 1B1. Toxicol Appl Pharmacol. 260:124–134. 2012. View Article : Google Scholar : PubMed/NCBI
24	Li W, Fan M, Chen Y, Zhao Q, Song C, Yan Y, Jin Y, Huang Z, Lin C and Wu J: Melatonin induces cell apoptosis in AGS cells through the activation of JNK and P38 MAPK and the suppression of nuclear factor-Kappa B: A novel therapeutic implication for gastric cancer. Cell Physiol Biochem. 37:2323–2338. 2015. View Article : Google Scholar : PubMed/NCBI
25	Khandrika L, Lieberman R, Koul S, Kumar B, Maroni P, Chandhoke R, Meacham RB and Koul HK: Hypoxia-associated p38 mitogen-activated protein kinase-mediated androgen receptor activation and increased HIF-1alpha levels contribute to emergence of an aggressive phenotype in prostate cancer. Oncogene. 28:1248–1260. 2009. View Article : Google Scholar : PubMed/NCBI
26	Tsai PW, Shiah SG, Lin MT, Wu CW and Kuo ML: Up-regulation of vascular endothelial growth factor C in breast cancer cells by heregulin-beta 1. A critical role of p38/nuclear factor-kappa B signaling pathway. J Biol Chem. 278:5750–5759. 2003. View Article : Google Scholar : PubMed/NCBI
27	Iyoda K, Sasaki Y, Horimoto M, Toyama T, Yakushijin T, Sakakibara M, Takehara T, Fujimoto J, Hori M, Wands JR and Hayashi N: Involvement of the p38 mitogen-activated protein kinase cascade in hepatocellular carcinoma. Cancer. 97:3017–3026. 2003. View Article : Google Scholar : PubMed/NCBI
28	Koul HK, Pal M and Koul S: Role of p38 MAP kinase signal transduction in solid tumors. Genes Cancer. 4:342–359. 2013. View Article : Google Scholar : PubMed/NCBI
29	Greten FR and Karin M: The IKK/NF-kappaB activation pathway-a target for prevention and treatment of cancer. Cancer Lett. 206:193–199. 2004. View Article : Google Scholar : PubMed/NCBI
30	Zhang X, Wu M, Jiang H, Hao J, Zhang Q, Zhu Q, Saren G, Zhang Y, Meng X and Yue X: Angiotensin II upregulates endothelial lipase expression via the NF-kappa B and MAPK signaling pathways. PLoS One. 9:e1076342014. View Article : Google Scholar : PubMed/NCBI
31	Van Waes C: Nuclear factor-kappa B in development, prevention and therapy of cancer. Clin Cancer Res. 13:1076–1082. 2007. View Article : Google Scholar : PubMed/NCBI
32	Li J, Jia H, Xie L, Wang X, Wang X, He H, Lin Y and Hu L: Association of constitutive nuclear factor-KappaB activation with aggressive aspects and poor prognosis in cervical cancer. Int J Gynecol Cancer. 19:1421–1426. 2009. View Article : Google Scholar : PubMed/NCBI